Heart failure with preserved ejection fraction (HFpEF) is increasing in incidence and has a higher prevalence compared with heart failure with reduced ejection fraction. So far, no effective treatment of HFpEF is available, due to its complex underlying pathophysiology and clinical heterogeneity. This article aims to provide an overview and a future perspective of transcriptomic biomarker research in HFpEF. Detailed characterisation of the HFpEF phenotype and its underlying molecular pathomechanisms may open new perspectives regarding early diagnosis, improved prognostication, new therapeutic targets and tailored therapies accounting for patient heterogeneity, which may improve quality of life. A combination of cross-sectional and longitudinal study designs with sufficiently large sample sizes are required to support this concept.
LHA ID: 84H299KF04-7
PubMed ID: 33042584
Projects: Genetical Statistics and Systems Biology
Publication type: Journal article
Journal: Card Fail Rev
Human Diseases: No Human Disease specified
Citation: Card Fail Rev. 2020 Sep 28;6:e24. doi: 10.15420/cfr.2019.19. eCollection 2020 Mar.
Date Published: 12th Oct 2020
Registered Mode: by PubMed ID
Created: 3rd Nov 2020 at 10:40